Yuyu Pharma Inc (000225) - Total Assets
Based on the latest financial reports, Yuyu Pharma Inc (000225) holds total assets worth ₩207.22 Billion KRW (≈ $140.43 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 000225 total equity for net asset value and shareholders' equity analysis.
Yuyu Pharma Inc - Total Assets Trend (2014–2025)
This chart illustrates how Yuyu Pharma Inc's total assets have evolved over time, based on quarterly financial data.
Yuyu Pharma Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Yuyu Pharma Inc's total assets of ₩207.22 Billion consist of 46.8% current assets and 53.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 14.0% |
| Accounts Receivable | ₩18.55 Billion | 9.0% |
| Inventory | ₩42.22 Billion | 20.4% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩2.68 Billion | 1.3% |
| Goodwill | ₩153.77 Million | 0.1% |
Asset Composition Trend (2014–2025)
This chart illustrates how Yuyu Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Yuyu Pharma Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Yuyu Pharma Inc's current assets represent 46.8% of total assets in 2025, an increase from 44.9% in 2014.
- Cash Position: Cash and equivalents constituted 14.0% of total assets in 2025, up from 11.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 2.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 20.4% of total assets.
Yuyu Pharma Inc Competitors by Total Assets
Key competitors of Yuyu Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Aspen Pharmacare Holdings Ltd
JSE:APN
|
South Africa | ZAC135.89 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥5.82 Billion |
|
Dezhan HealthCare Co Ltd
SHE:000813
|
China | CN¥5.23 Billion |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907
|
China | CN¥2.00 Billion |
|
Jiangsu Jibeier Pharmaceutical Co Ltd
SHG:688566
|
China | CN¥2.64 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.53 Billion |
Yuyu Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.64 | 1.58 | 2.87 |
| Quick Ratio | 0.93 | 0.98 | 1.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩37.97 Billion | ₩37.47 Billion | ₩45.58 Billion |
Yuyu Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Yuyu Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -0.2% |
| Total Assets | ₩207.22 Billion |
| Market Capitalization | $17.61 Million USD |
Valuation Analysis
Below Book Valuation: The market values Yuyu Pharma Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Yuyu Pharma Inc's assets decreased by 0.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Yuyu Pharma Inc (2014–2025)
The table below shows the annual total assets of Yuyu Pharma Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩207.22 Billion ≈ $140.43 Million |
-0.22% |
| 2024-12-31 | ₩207.69 Billion ≈ $140.75 Million |
+4.78% |
| 2023-12-31 | ₩198.21 Billion ≈ $134.33 Million |
+1.54% |
| 2022-12-31 | ₩195.21 Billion ≈ $132.29 Million |
+1.15% |
| 2021-12-31 | ₩192.99 Billion ≈ $130.78 Million |
+24.59% |
| 2020-12-31 | ₩154.90 Billion ≈ $104.97 Million |
+12.48% |
| 2019-12-31 | ₩137.72 Billion ≈ $93.33 Million |
+1.84% |
| 2018-12-31 | ₩135.23 Billion ≈ $91.64 Million |
+11.31% |
| 2017-12-31 | ₩121.49 Billion ≈ $82.33 Million |
+9.16% |
| 2016-12-31 | ₩111.30 Billion ≈ $75.43 Million |
+6.68% |
| 2015-12-31 | ₩104.33 Billion ≈ $70.70 Million |
+2.89% |
| 2014-12-31 | ₩101.40 Billion ≈ $68.72 Million |
-- |
About Yuyu Pharma Inc
Yuyu Pharma, Inc. develops and markets pharmaceutical products in Korea and United States. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc.… Read more